Evidence map›Paper›PMID 21171956›Full record

ReviewRecent patents on biotechnology2010

Developments in high-yield system expressed vaccines and immunotherapy.

Marissa Geels, Kaiming Ye

Abstract readReview
In one paragraph

Review in Recent patents on biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marissa GeelsBiomedical Engineering Program, College of Engineering, University of Arkansas, 203 Engineering Hall, Fayetteville, AR 72701, USA.
Kaiming Ye

Funding

HA Surface Presented Yeast Flu Vaccine and Its Enhancement by CD154 CodisplayR01AI078357 · NIAID · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI YE, KAIMING · 2009 to 2012
$1.3M
NIAID NIH HHS R01 AI078357
6 · The paper itself

Abstract

Conventional vaccine production techniques are outdated, leaving the world defenseless to viruses and pathogens. Successful protection necessitates the innovation of strategies that can generate an induced defensive humoral and cellular response with: ease of mass production, nominal side-effects, and controlled design specificity, all while being cost effective. Fortunately, technology exists to facilitate such advances in this billion dollar industry and this review is focused on recent publications and patents which hold promise to revolutionize the fight against pathogenic illnesses.

Indexed as

ImmunotherapyReassortant VirusesBacterial VaccinesCost-Benefit AnalysisDNA, RecombinantDrug IndustryGenetic VectorsHumansInfluenza VaccinesMembrane ProteinsPatents as TopicRecombinant ProteinsVaccinesVaccines, DNAVaccines, SyntheticBacterial VaccinesDNA, RecombinantInfluenza VaccinesMembrane ProteinsRecombinant ProteinsVaccinesVaccines, DNAVaccines, Synthetic

Identifiers

PMID21171956
PMCPMC3020102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.